checkAd

     149  0 Kommentare Evotec SE to Announce Preliminary Financial Results for Fiscal Year 2022 on 28 March 2023

    HAMBURG, GERMANY / ACCESSWIRE / March 21, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX)(ISIN: DE0005664809)(NASDAQ:EVO) will announce its preliminary financial results for 2022 on Tuesday, 28 March 2023. The Company is going to hold a …

    HAMBURG, GERMANY / ACCESSWIRE / March 21, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX)(ISIN: DE0005664809)(NASDAQ:EVO) will announce its preliminary financial results for 2022 on Tuesday, 28 March 2023.

    Evotec SE, Monday, October 17, 2022, Press release picture
    Anzeige 
    Handeln Sie Ihre Einschätzung zu Evotec SE!
    Long
    13,23€
    Basispreis
    1,59
    Ask
    × 9,84
    Hebel
    Short
    15,75€
    Basispreis
    1,42
    Ask
    × 9,70
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in English.

    Conference call details

    Date: Tuesday, 28 March 2023
    Time: 02.00 pm CEST (08.00 am EDT, 01.00 pm BST)

    To join via phone , please pre-register via the following link: https://services.choruscall.it/DiamondPassRegistration/register?confir ...

    You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call.

    A simultaneous slide presentation for participants dialling in via phone is available at https://www.webcast-eqs.com/evotec-2022-prelim/no-audio .

    Webcast details

    To join the audio webcast and to access the presentation slides you will find a link on our homepage www.evotec.com shortly before the event.

    The on-demand version of the webcast will be available on our website: https://www.evotec.com/en/investor-relations/publications .

    ABOUT EVOTEC SE

    Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,500 highly qualified people. The Company's 17 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn .

    FORWARD-LOOKING STATEMENTS

    This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

    Media Contact Evotec SE:
    Gabriele Hansen, SVP Head of Global Corporate Communications, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com

    Hinnerk Rohwedder, Director of Global Corporate Communications, Tel.: +49.(0)151 4070-4843, hinnerk.rohwedder@evotec.com

    IR Contact Evotec SE:
    Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, volker.braun@evotec.com

    SOURCE: Evotec SE



    View source version on accesswire.com:
    https://www.accesswire.com/744883/Evotec-SE-to-Announce-Preliminary-Fi ...


    The Evotec Stock at the time of publication of the news with a raise of +2,33 % to 18,21EUR on Tradegate stock exchange (21. März 2023, 12:09 Uhr).
    Der Analyst erwartet ein Kursziel von 15,48, was eine Steigerung von +7,00% zum aktuellen Kurs entspricht. Mit diesen Produkten können Sie die Kurserwartungen des Analysten übertreffen.
    Übernehmen
    Für Ihre Einstellungen haben wir keine weiteren passenden Produkte gefunden.
    Bitte verändern Sie Kursziel, Zeitraum oder Emittent.
    Alternativ können Sie auch unsere Derivate-Suchen verwenden
    Knock-Out-Suche | Optionsschein-Suche | Zertifikate-Suche
    WerbungDisclaimer


    Accesswire
    0 Follower
    Autor folgen
    Mehr anzeigen
    We’re a newswire service standout and fast becoming an industry disruptor. We provide regional, national and global news to thousands of clients around the world. We’re also leading the way in social engagement, targeting and analytics.
    Mehr anzeigen

    Verfasst von Accesswire
    Evotec SE to Announce Preliminary Financial Results for Fiscal Year 2022 on 28 March 2023 HAMBURG, GERMANY / ACCESSWIRE / March 21, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX)(ISIN: DE0005664809)(NASDAQ:EVO) will announce its preliminary financial results for 2022 on Tuesday, 28 March 2023. The Company is going to hold a …

    Schreibe Deinen Kommentar

    Disclaimer